PTPN22 and neoplasm: Our previous experiments determined an enhanced capacity of Ptpn22–/– CD8+ T cells to produce IFN-γ and TNF in response to low-affinity peptide antigens (14, 15) and mediate tumor rejection upon ACT (8).